Axsome Therapeutics Biotech Company Impresses with Strong Pipeline!
Reading Time: 1 minute
Business Driver: Axsome Therapeutics (AXSM) specializes in the development of new treatments for central nervous system (CNS) disorders. With the antidepressant Auvelity (AXS-05), they have a revenue-generating product. In this context, they recently reported a significant success. Accordingly, the generic manufacturer Teva Pharmaceuticals will be allowed to market its copycat product for the antidepressant no earlier than March 31, 2039. On December 31, the FDA granted an accelerated approval review for the core product AXS-05 for the treatment...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
